MYD88 L265P in DLBCL marks the ABC/MCD molecular subtype (Schmitz et al. NEJM 2018; Wrigh...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MYD88-L265P-DLBCL-NOS |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-CIVIC SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-MYD88-L265P |
|---|---|
| Variant | L265P (often with CD79B mutation — MCD/C5 cluster) |
| Disease | DIS-DLBCL-NOS |
| ESCAT tier | IIB |
| Recommended combinations | R-CHOP + ibrutinib (off-label, MCD/genetically-selected), pola-R-CHP (1L; POLARIX — not MYD88-selected but consider), CAR-T axi-cel / liso-cel (R/R) |
| Evidence summary | MYD88 L265P in DLBCL marks the ABC/MCD molecular subtype (Schmitz et al. NEJM 2018; Wright Cancer Cell 2020). Ibrutinib improves OS specifically in MCD/N1/A53 subtypes when added to R-CHOP (PHOENIX subgroup analysis, Wilson et al. Cancer Cell 2021). Not formally approved as biomarker-selected indication in DLBCL; basket trials ongoing. |
Notes
ESCAT IIB. OncoKB Level 3A. MYD88+CD79B co-mutation defines MCD subtype with strongest BTKi rationale. Not on FDA DLBCL label.
Used By
No reverse references found in the YAML corpus.